PBLS Parabilis Medicines, Inc.
Executive Summary
Parabilis Medicines priced its IPO of 33,500,000 shares at $20.00/share, raising approximately $623.1 million in gross proceeds (before underwriting discounts and expenses). Additionally, Regeneron is investing $75.0 million in a concurrent private placement at $18.00/share (90% of the IPO price). Combined with a $50.0 million upfront from Regeneron under a May 2026 collaboration, the company expects total pro forma as-adjusted cash of ~$1.02 billion, sufficient to fund operations into H2 2029.
Key Financial Metrics
Actionable Insight
The IPO prices a pre-revenue biotech at a ~$2.3B market cap (based on 116.6M shares post-offering at $20). Key catalysts to watch: initiation of Phase 3 registrational trial for zolucatetide in desmoid tumors (expected H1 2027), data from ongoing Phase 1/2 trials across multiple indications, and progress of ERG/ARON degrader preclinical programs. The ~$1.0B cash runway into H2 2029 reduces near-term dilution risk but shifts focus to clinical execution.
Key Facts
- 33,500,000 shares offered at $20.00/share, total gross proceeds $670,000,000
- Underwriters' overallotment option of 5,025,000 additional shares
- Regeneron concurrent private placement: 4,166,666 shares at $18.00/share ($75.0M total)
- Net proceeds to company: ~$618.2M from IPO, plus ~$75.0M from private placement
- Pro forma as-adjusted cash position: $1,022,239,000 as of March 31, 2026
- Cash runway extended into H2 2029; funds Phase 3 desmoid tumor trial, pipeline expansion
Financial Impact
$670M gross IPO proceeds + $75M Regeneron PIPE = $745M total gross proceeds; net proceeds ~$693.2M after underwriting and expenses
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products; high risk of trial failure
- Novel modality (Helicons) with unproven regulatory path
- Dilution from 33.5M new shares (28.4% of post-IPO float) and option overhang
- Substantial additional capital likely needed before reaching profitability
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-265983 |
| Document: 0001193125-26-265983-index-headers.html | 0001193125-26-265983 |
| Document: 0001193125-26-265983-index.html | 0001193125-26-265983 |
| Document: 0001193125-26-265983.txt | 0001193125-26-265983 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $30.30 awaiting T+20 | awaiting T+20 | — | $27.26 (−10.03%) |
|
Jun 10, 2026
4d ago
|
424B4
| $32.16 awaiting T+20 | awaiting T+20 | — | $27.26 (−15.24%) |
|
Jun 10, 2026
5d ago
|
EFFECT
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access